Return to Clinical Trials Search Results
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of HMI-103 Administered Intravenously in Adult Participants with Classical PKU Due to PAH Deficiency.
Primary: Determine the safety of a single administration of HMI-103
To evaluate the efficacy of HMI-103on reduction of plasma Pheconcentration at each dose level
Primary: Determine the safety of a single administration of HMI-103
To evaluate the efficacy of HMI-103on reduction of plasma Pheconcentration at each dose level
Recruitment Status
Current Studies